The 3rd Ophthalmic Drug Delivery Summit addresses innovations in ophthalmic drug delivery methods and devices, focusing on achieving minimally invasive, sustained-release solutions for treating eye diseases.
Topics
- Suprachoroidal Delivery in Gene Therapy to Capitalize on Ocular Anatomy
- Overcoming Hurdles in Ophthalmic Clinical Trial Design to Spearhead Development
- The State of Play for Ophthalmic Drug Delivery to the Retina
- Advancing Retinal Therapy With Sustained Release Implants to Reduce Treatment Frequency
- The Journey of Genentech’s Susvimo Port Delivery System’s from Challenges to FDA Reapproval
- Advancements in Large Volume Formulations & High Viscosity Injectable Drug Delivery
- Drug Delivery Mechanics for Extended Release Implants
- Establishing Robust Clinical Trial Design to Overcome Past Failings
- Overcoming Inflammatory Responses to Maximize Therapeutic Effect
- The Evolving Landscape of Regulatory Approvals for Combination Products
- Navigating the Safety Landscape of Novel Drug Delivery
- Advancing Drug Formulations & Combinations to Achieve Sustained Release
- Advancing Targeted, Compartmentalized & Long-Acting Depot Delivery: Synergistic Combination of Particulate Formulation & Suprachoroidal Route of Administration
- Enhancing Ocular Drug Delivery Through Combined Microparticles, Nanoparticles & Hydrogels
- Mastering Suprachoroidal Delivery to Increase Distribution & Durability
- Expanding the Potential of the Suprachoroidal Space in Retinal Therapy
- Considering Non-Invasive Administration of Medications for Retinal Diseases : a Mechanism of Action Perspective
- Comparing of Existing Ophthalmic Models Approaches to Supercharge Development
- Utilizing Preclinical & Computational Models for Predicting Human Ophthalmic Drug Behavior
- Delivery Effective Cell & Gene Therapies to the Eye to Halt Vision Loss
- Optimizing Current Suprachoroidal & Subretinal Delivery of AAV Gene Therapies
- Enhancing Cell & Gene Therapies With Advanced Hydrogel Platforms
- Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results
- Innovations with Topical & Oral Medications & the Path to Regulatory Success
- Considering Systemic Administration of PPARalpha Agonist for the Treatment of Diabetic Retinopathy & AMD
